{
  "abstract": "The unpredictable nature of the SLE disease activity makes its management particularly challenging. Current treatment options for SLE focus on managing the inflammatory status, decreasing the symptoms and reducing the frequency and severity of flares. Glucocorticoids (GCs) are a common and still essential treatment for SLE due to their rapid and potent anti-inflammatory and immunosuppressive effects. However, prolonged GC use is linked to various adverse events like infections, osteoporosis, avascular necrosis, cataracts and diabetes, contributing crucially to organ damage. 1 Consequently, the most recently updated European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of SLE advocate for using the lowest possible prednisone-equivalent GC dose (≤5.0 mg/day) and discontinuing use when feasible, emphasising the importance of GC-sparing agents, such as biologics or immunosuppressives.1",
  "authors": [
    {
      "affiliations": [
        "Rheumatology, Complejo Hospitalario Doctor Negrin, Las Palmas de Gran Canaria, Spain"
      ],
      "name": "Iñigo Rua-Figueroa"
    },
    {
      "affiliations": [
        "Hospital Clinic of Barcelona, Barcelona, Spain"
      ],
      "name": "Ricard Cervera"
    },
    {
      "affiliations": [
        "Rheumatology, University Hospital Complex of A Coruña, A Coruña, Spain"
      ],
      "name": "Mercedes Freire-González"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain"
      ],
      "name": "Ana Isabel Turrión Nieves"
    },
    {
      "affiliations": [
        "Rheumatology Department, Hospital Vall d’Hebron, Barcelona, Spain"
      ],
      "name": "Josefina Cortés-Hernández"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitari de Santa Creu i Sant Pau, Barcelona, Spain"
      ],
      "name": "Iván Castellvi"
    },
    {
      "affiliations": [
        "Internal Medicine, Rio Hortega University Hospital, Valladolid, Spain"
      ],
      "name": "Julia Barbado Ajo"
    },
    {
      "affiliations": [
        "Hospital del Mar, Barcelona, Spain"
      ],
      "name": "Tarek Salman"
    },
    {
      "affiliations": [
        "Rheumatology, Hospital Universitario Araba, Vitoria-Gasteiz, Spain"
      ],
      "name": "Jaime Calvo Alén"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain"
      ],
      "name": "Nuria Lozano-Rivas"
    },
    {
      "affiliations": [
        "Autoimmune Diseases Unit, Hospital de Especialidades San Cecilio, Granada, Spain"
      ],
      "name": "Norberto Ortego-Centeno"
    },
    {
      "affiliations": [
        "Department of Nephrology, Fundación Puigvert, Barcelona, Spain"
      ],
      "name": "Monserrat Diaz-Encarnación"
    },
    {
      "affiliations": [
        "AstraZeneca Sweden, Mölndal, Sweden"
      ],
      "name": "Bo Ding"
    },
    {
      "affiliations": [
        "Medical Department, AstraZeneca Farmacéutica Spain, Madrid, Spain"
      ],
      "name": "Marta Galvez-Fernandez"
    },
    {
      "affiliations": [
        "Medical Department, AstraZeneca Farmacéutica Spain, Madrid, Spain"
      ],
      "name": "Noemí Bahamontes-Rosa"
    },
    {
      "affiliations": [
        "Rheumatology, Inst Invest Biomed Vigo Spain, Vigo, Spain"
      ],
      "name": "José María Pego-Reigosa"
    },
    {
      "affiliations": [],
      "name": "the Spanish SLE Prospective Observational Cohort Study (SPOCS)"
    }
  ],
  "title": "Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data",
  "uid": "50aa2ec1-56c0-5e28-8f28-1803192a318e"
}